GL
Globe Life Inc
$
131.590
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
133.980
Open
132.790
VWAP
132.12
Vol
82.79K
Mkt Cap
10.60B
Low
131.050
Amount
10.94M
EV/EBITDA(TTM)
8.18
Total Shares
92.27M
EV
13.01B
EV/OCF(TTM)
9.41
P/S(TTM)
1.87
Globe Life Inc. is an insurance holding company. Its primary subsidiaries are Globe Life And Accident Insurance Company, American Income Life Insurance Company, Liberty National Life Insurance Company, Family Heritage Life Insurance Company of America, and United American Insurance Company. The Company’s segments include life insurance, supplemental health insurance, and investments. Life insurance products include traditional whole life and term life insurance. The Company offers Medicare Supplement and limited-benefit supplemental health insurance products that include accident, cancer, critical illness, heart, intensive care, and other health products. These products are designed to supplement health coverage that applicants already own. Medicare Supplements are offered to enrollees in the traditional fee-for-service Medicare program. Medicare Supplement plans are standardized by federal regulation and are designed to pay deductibles and co-payments not paid by Medicare.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
1.57B
+6.29%
3.717
+13.66%
1.56B
+5.13%
3.533
+15.09%
1.53B
+4.56%
3.437
+9.45%
Estimates Revision
The market is revising Downward the revenue expectations for Globe Life Inc. (GL) for FY2025, with the revenue forecasts being adjusted by -0.16% over the past three months. During the same period, the stock price has changed by -5.03%.
Revenue Estimates for FY2025
Revise Downward
-0.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.59%
In Past 3 Month
Stock Price
Go Down
-5.03%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast GL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GL is 167.88 USD with a low forecast of 145.00 USD and a high forecast of 182.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 131.590
Low
145.00
Averages
167.88
High
182.00
Current: 131.590
Low
145.00
Averages
167.88
High
182.00
Keefe Bruyette
Outperform
maintain
$160 -> $162
2025-10-28
Reason
Keefe Bruyette
Price Target
$160 -> $162
2025-10-28
maintain
Outperform
Reason
Keefe Bruyette raised the firm's price target on Globe Life to $162 from $160 and keeps an Outperform rating on the shares. The primary near-term risk is a lack of further catalysts, the analyst tells investors in a research note.
Truist
Mark Hughes
Buy
maintain
$150 -> $158
2025-10-24
Reason
Truist
Mark Hughes
Price Target
$150 -> $158
2025-10-24
maintain
Buy
Reason
Truist analyst Mark Hughes raised the firm's price target on Globe Life to $158 from $150 and keeps a Buy rating on the shares after its Q3 earnings beat. The firm is raising its price target, which assumes the stock trades at just under 10.5-times next year's earnings, still below its long-term norm in the low-double-digits, the analyst tells investors in a research note.
Wells Fargo
Overweight
maintain
$172 -> $170
2025-10-24
Reason
Wells Fargo
Price Target
$172 -> $170
2025-10-24
maintain
Overweight
Reason
Wells Fargo lowered the firm's price target on Globe Life to $170 from $172 and keeps an Overweight rating on the shares. The firm notes Globe Life was volatile as weak top line growth and lackluster agent count growth was partially offset by management commentary on strong life margins for 2026 and higher buybacks.
Morgan Stanley
Overweight
maintain
$166 -> $171
2025-08-18
Reason
Morgan Stanley
Price Target
$166 -> $171
2025-08-18
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Globe Life to $171 from $166 and keeps an Overweight rating on the shares. Following Q2 results, the firm is updating its price targets for stocks in the Life Insurance segment under its coverage, the analyst tells investors. Nearly half of the life insurers under its coverage beat expectations on a reported basis and most exceeded expectations on a core basis, the firm adds. Morgan Stanley notes the earnings beats were largely driven by selective favorable underwriting, better than expected performance of macro-sensitive segments, or both.
Morgan Stanley
Equal Weight -> Overweight
upgrade
$135 -> $166
2025-08-05
Reason
Morgan Stanley
Price Target
$135 -> $166
2025-08-05
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded Globe Life to Overweight from Equal Weight with a price target of $166, up from $135. The firm believes the end of SEC and DOJ investigations should remove significant uncertainty on the the shares. With the investigative headwinds removed, investor focus should shift back to Globe Life's fundamentals and "steady" earnings growth, the analyst tells investors in a research note. Morgan Stanley sees a path to multiple expansion for the shares.
BMO Capital
Jack Matten
Market Perform
maintain
$114 -> $149
2025-07-30
Reason
BMO Capital
Jack Matten
Price Target
$114 -> $149
2025-07-30
maintain
Market Perform
Reason
BMO Capital analyst Jack Matten raised the firm's price target on Globe Life to $149 from $114 and keeps a Market Perform rating on the shares after its Q2 results. The firm cites the company's positive underlying trends at its Direct to Consumer arm which helps exclusive agency sales via leads+analytics, along with the removal of a valuation overhang from inquiries and investigations, the analyst tells investors in a research note. The stock's valuation also still embeds some discount versus long-term averages, BMO added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Globe Life Inc (GL.N) is 9.12, compared to its 5-year average forward P/E of 10.58. For a more detailed relative valuation and DCF analysis to assess Globe Life Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
10.58
Current PE
9.12
Overvalued PE
12.52
Undervalued PE
8.64
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
9.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.12
Undervalued EV/EBITDA
7.94
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.31
Current PS
133.16
Overvalued PS
17.18
Undervalued PS
-10.56
Financials
Annual
Quarterly
FY2025Q3
YoY :
+3.96%
1.51B
Total Revenue
FY2025Q3
YoY :
+25.30%
515.83M
Operating Profit
FY2025Q3
YoY :
+28.00%
387.84M
Net Income after Tax
FY2025Q3
YoY :
+37.50%
4.73
EPS - Diluted
FY2025Q2
YoY :
-17.25%
294.99M
Free Cash Flow
FY2025Q3
YoY :
-13.45%
20.97
FCF Margin - %
FY2025Q3
YoY :
+23.10%
25.63
Net Margin - %
FY2025Q3
YoY :
-3.61%
16.01
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 1656.78% over the last month.
Sold
0-3
Months
12.9M
USD
2
3-6
Months
16.7M
USD
8
6-9
Months
2.5M
USD
4
0-12
Months
16.6M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 1440.51% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
736.5K
Volume
2
0-12
Months
47.8K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
70.0K
Volume
Months
0-12
5
165.5K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
16.0K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
8.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 1656.78% over the last month.
Sold
0-3
Months
12.9M
USD
2
3-6
Months
16.7M
USD
8
6-9
Months
2.5M
USD
4
0-12
Months
16.6M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GL News & Events
Events Timeline
2025-10-28 (ET)
2025-10-28
09:02:46
Globe Life Partners with North Texas Food Bank for Three-Year Initiative
2025-10-22 (ET)
2025-10-22
16:14:08
Globe Life announces Q3 operating EPS of $4.81, surpassing consensus estimate of $4.54.
2025-10-07 (ET)
2025-10-07
09:13:58
December Gold Surpasses $4,000 an Ounce, Boosting Gold Mining Stocks
Sign Up For More Events
Sign Up For More Events
News
6.0
11-12Yahoo FinanceAM Best Reconfirms Credit Ratings for Globe Life Inc. and Its Subsidiaries
8.0
11-06PRnewswireGLOBE LIFE INC. DECLARES DIVIDEND
4.0
11-04TipRanksAnalysts Predict Over 20% Upside for These 3 "Strong Buy" Value Stocks – 11/4/2025
Sign Up For More News
People Also Watch
MGM
MGM Resorts International
32.590
USD
-0.70%
RBC
RBC Bearings Inc
434.450
USD
+0.67%
WPP
WPP PLC
18.770
USD
+1.19%
PRI
Primerica Inc
252.410
USD
-0.62%
AIT
Applied Industrial Technologies Inc
248.385
USD
-1.00%
RRC
Range Resources Corp
37.980
USD
-0.11%
PNW
Pinnacle West Capital Corp
87.970
USD
-0.96%
BBDO
Banco Bradesco SA
3.200
USD
0.00%
UWMC
UWM Holdings Corp
5.130
USD
-0.19%
WAL
Western Alliance Bancorp
77.910
USD
-0.35%
FAQ
What is Globe Life Inc (GL) stock price today?
The current price of GL is 131.59 USD — it has decreased -1.18 % in the last trading day.
What is Globe Life Inc (GL)'s business?
What is the price predicton of GL Stock?
What is Globe Life Inc (GL)'s revenue for the last quarter?
What is Globe Life Inc (GL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Globe Life Inc (GL)'s fundamentals?
How many employees does Globe Life Inc (GL). have?